There are published data indicating that the mouse lymphoma TK assay (MLA) has an unacceptably high incidence of positive results, hence it was decided to review the MLA data generated in this laboratory for potential drug candidates. Of the 355 compounds tested, only 52 (15%) gave positive results so, even if it is assumed that all of these are non-carcinogens, the incidence of 'false positive' predictions of carcinogenicity is much lower than the 61% apparent from analysis of the literature. Furthermore, only 19 compounds (5%) were positive by a mechanism that could not be associated with the compounds primary pharmacological activity or positive responses in other genotoxicity assays. It should be noted that the majority of these compounds were not bacterial mutagens so, in most cases, the positive results were an additional indicator of genotoxicity. However, data are not available to assess any risk they might present. At least for pharmaceuticals, it appears that the MLA does not generate as many positive results as is commonly believed, and it is against this incidence that the performance of other in vitro genotoxicity tests should be compared. The predictive accuracy of the program MultiCase MC4PC was also examined using these results. The sensitivity and specificity were found to be 62 and 38%, respectively; in fact, 62% of all compounds were predicted to be positive irrespective of whether they were actually positive or negative. It was concluded that, in its current state of development, M4PC cannot be considered sufficiently accurate to be used to predict the activity of pharmaceuticals in the MLA.
Introduction
The mouse lymphoma assay (MLA) detects mutation at the thymidine kinase (tk) locus of L5178Y tk þ/À cells and is a wellestablished in vitro genotoxicity test. The initial method in which the cells were cloned in soft agar was validated by Clive in the 1970s (1, 2) , with a microtitre method later developed by Cole in the 1980s (3) . Along with other in vitro mammalian cell genotoxicity assays, the accuracy of the MLA for identifying carcinogens has often been questioned, particularly for its lack of specificity i.e. 'over sensitivity' (4) . Some of this original censure was later found to be groundless once protocols that excluded testing to excessive levels of toxicity, pH or osmolality were introduced (5, 6) . Hence during the early 1990s, the reliability of the assay was re-evaluated and the MLA was concluded to be a valuable complement to the Ames test and cytogenetic assays (7) . Furthermore, comparative trials in the 1990s demonstrated good concordance between the MLA and other in vitro clastogenicity assays (8) and, accordingly, the MLA was adopted as an alternative to them in the standard battery of genotoxicity tests recommended in the ICH S2B guideline for pharmaceutical safety evaluation (9) . It was also included in the Organisation for Economic Co-operation and Development Guideline for the Testing of Chemicals No. 476 (10) . However, the question of the predictive accuracy of the MLA was highlighted again in 2005 in the retrospective review of genotoxicity data from the ICH recommended tests by Kirkland et al. (11) , which showed that it correctly identified only 41 of 105 non-carcinogens i.e. for this set of compounds the 'false positive' rate was as high as 61%. While this review included a wide variety of chemicals and did not focus on pharmaceuticals, it was interpreted as evidence that the 'over sensitivity' of the MLA was a general phenomenon.
Although the data reviewed by Kirkland et al. are taken from the open literature, it is possible that they may not accurately reflect the performance of the MLA as it is currently used to test pharmaceuticals. Therefore, in order to determine the incidence of positive results obtained with pharmaceuticals in this laboratory, a retrospective analysis was made of 355 compounds tested at AstraZeneca (AZ, Alderley Park, UK) between 2001 and 2010. In addition, in silico prediction of the results was performed using MultiCase (MCASE) MC4PC in order to estimate its potential value as an initial screen.
Materials and methods

Cell line and culture conditions
Mouse lymphoma L5178Y cells, clone 3.7.2C, were obtained by AZ from Dr J. Cole (MRC Cell Mutation Unit, University of Sussex, Brighton, UK). The provenance of these cells is known and it can be documented that the master stocks at AZ were grown for no more than 15 days in culture since Dr D. Clive supplied the original vial to Cole in 1978. The standard procedure at AZ ensured cryopreserved working stocks were prepared from the master stock after cleansing pre-existing trifluorothymidine (TFT) mutants with methotrexate within a further week. For every individual test, an ampoule of working stock cells was recovered and grown for up to 7 days before use. Consequently, all the tests reported here used cells that had been grown for a maximum of 4 weeks in culture, with a single cleansing in methotrexate, from the sample supplied by Clive to Cole in 1978. The cells were confirmed to be free from mycoplasma infection and shown to have the published karyotype (12), specifically X0 der 5t(5; 15), der9t(9; 6) robertsonian fusion 12 and 13, del 14 þ 15(t15; 5), þ15(t15; 18,14), der 15, À15q, der 18t(18; 6) and two copies of chromosome 11 detected by fluorescent in situ hybridisation (Ann Doherty, in house AZ data). Cells were cultured in RPMI 1640 medium (Invitrogen, Paisley, UK) supplemented with 10% heat inactivated donor horse serum (DHS), 2 mmol/l L-glutamine, 2 mmol/l sodium pyruvate, 1% Pluronic F68, 200 IU/ml penicillin and 200 lg/ml streptomycin and maintained at 37°C in a humidified atmosphere of 5% CO 2 in air. Cells were plated for determination of the TK À/À phenotype in RPMI 1640 containing 20% DHS supplemented with 4 lg/ml TFT.
Metabolic activation
For treatments in the presence of exogenous metabolism, S9 from the livers of Aroclor 1254-treated rats was purchased from Molecular Toxicology Inc.
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(Boone, NC, USA) and stored frozen at a temperature of À70°C or below until use. On the day of use, S9 mix was prepared by the addition of culture medium containing cofactors for reduced nicotinamide adenine dinucleotide phosphate generation to the S9 fraction. A final S9 concentration of 4% vol/vol was used for tests from 2001 to 2007 and 2% vol/vol subsequently.
Mutation at the tk locus
Treatments were performed essentially as described by Clements (13) . All 355 compounds were tested using 3-or 4-h exposure in the presence and absence of S9. Ninety-nine compounds were also tested using 24-h exposure in the absence of S9; the longer period of exposure was not usually included for initial tests on compounds in early development that were not intended to support regulatory submissions. Under all conditions, the highest concentrations analysed were determined by solubility in tissue culture medium (including analysis of the lowest precipitating concentration) or toxicity (to $10-20% relative total growth). All the compounds were either toxic or insoluble at concentrations ,10 mmol/l or 5000 lg/ml. The global evaluation factor (increase in mutant frequency of 126 Â 10 À6 above concurrent control) was used for assessment (14) and was retrospectively applied to some data. Only one of the results was changed (from positive to negative) by this re-analysis.
Bacterial mutation tests
All of the 355 compounds tested in the MLA were also tested in a five-strain bacterial mutagenicity test using the plate incorporation method. The majority of tests included Salmonella typhimurium strains TA1535, TA100, TA98 and TA1537 plus Escherichia coli WP2 uvrA/pKM101. Compounds from AZ's infection portfolio were tested using the S.typhimurium strain TA102 rather than the E.coli strain. An increase in the number of revertant colonies was considered to be significant if it exceeded 2-fold the concurrent solvent control level for each strain.
MCASE MC4PC analysis
The MLA activity of 338 of the 355 compounds was predicted using the ALM module of MC4PC provided by MCASE, Inc. (15) . The standard simplified molecular input line entry specification format was used as the entry and the 'expert call' produced by MCASE was used as the activity output. MC4PC does provide several qualifications for the activity calls and these 'summary expert calls' were all 'equivocal' so the simple expert call was used. No MLA result generated at AZ was put into the MCASE learning set.
Results
MLA
Of the 355 compounds tested in the presence and absence of S9, 303 (85%) were concluded to be negative and 52 (15%) positive (Figure 1 ) all of which were active at concentrations ,1 mmol/l. Of the 99 compounds tested in all three exposure conditions, six (6%) were positive using 3/4-h exposure þ/ÀS9
and only a further two (2%) were positive using 24-h exposure in the absence of S9. These data indicate that few compounds are uniquely positive in the absence of S9 and the overall incidence of positive results is not significantly increased by using the extended exposure period.
Of the 52 compounds that were positive under any test condition, 36 (69%) were active in the presence and absence of S9, 12 (23%) were positive only in the presence of S9 and 4 (8%) were positive only in the absence of S9, using 3/4-h and/ or 24-h exposure.
The genotoxic mechanism of the 12 compounds that were positive only in the presence of S9 was considered unlikely to be due to their primary pharmacological activity since none was a prodrug. Of the remaining 40 positive compounds, 19 were cancer therapy drugs for which the primary pharmacological target was inhibition of either a kinase or DNA polymerase, both of which have been shown to be mechanisms for in vitro genotoxicity (16, 17) . A further 10 of the positive compounds were anti-infectives for which the primary pharmacological target was inhibition of either topoisomerase(s) or protein synthesis, both of which have also been shown to cause in vitro genotoxicity (18, 19) . One further compound was a metabolite that had previously been shown to be a mutagen. In total, of the 52 positive compounds, 30 had (or were intended to have) pharmacological activity that has been associated with genotoxicity in mammalian cells. Hence, only 22 (6%) of 355 compounds tested gave positive results by a mechanism that could not be explained by a possible relation to their primary pharmacological activity. Of these 22 compounds, 3 were also positive in either a bacterial mutation assay or an in vivo bone marrow micronucleus test, indicating that the positive MLA result was likely to have been a consequence of real genotoxity (Figure 2) . In summary, of 355 compounds tested over a 10-year period in this laboratory, only 52 (15%) were positive in the MLA and only 19 (5%) could be described as genuinely unexpected.
Ames results
Of the 355 compounds tested in the MLA, 10 were positive in the Ames test (3%) and 7 of these 10 were from AZ's infection portfolio for which the primary pharmacological target was inhibition of topoisomerase (gyrase or topoisomerase IV). As expected, all seven of these anti-infective compounds were positive in the excision repair proficient strain TA102 (20) . The other positive compounds were two monocyclic aromatic amines, for which the positive Ames response was not unexpected (21) , and one other compound of unknown genotoxic mechanism. Seven of the 10 Ames positive compounds were also positive in the MLA, the exceptions being the two small aromatic amines and one anti-infective. The latter was tested to only 1 mmol/l, that elicited little cytotoxicity but additional testing to higher concentrations was not considered necessary in view of the positive Ames test result.
MCASE MC4PC analysis results
In total, 338 of the compounds tested in the MLA at AZ were analysed for structural alert relationships using MC4PC. Of these, 209 (62%) were predicted to be positive. Surprisingly, there was no difference in the positive prediction rate between compounds that were actually positive or negative in the MLA with 177/286 (62%) of the negative compounds and 32/52 (also 62%) of the positives predicted to be positive. Hence, the overall predictivity of MC4PC for the MLA results obtained in this laboratory was sensitivity 62% (32/52), specificity 38% (109/286) and concordance 42% (n 5 338).
Discussion
Although cancer bioassay data are not available for these compounds, because 97% of them are not bacterial mutagens and all were tested as potential drug substances, it must be assumed that the majority are probably not DNA-reactive carcinogens. However, additional data are not available to assess any risk they might present. Even if none of them is a carcinogen, the data generated in this laboratory contradict the conclusion from the literature review that shows that the MLA has a false positive rate of up to 61%. In fact, the incidence of positive results from this laboratory is consistent with those for pharmaceuticals in general. Of marketed drugs listed in the 2008 US Physicians' Desk Reference (PDR), only 20% (32/163) are reported to be positive in the MLA although these excluded most cytotoxic anticancer and antiviral drugs (all with known mechanistic genotoxicity), steroids with classspecific genotoxicity and biological or peptide drugs (22) . A slightly higher incidence, 27% (28/104) was seen in all drugs submitted to the German regulatory authority (BfArM) during the 1990s but no specific drug types were omitted from this analysis (23) . It should be noted that in both the PDR and BfArM data sets, the incidence of positive results in in vitro cytogenetics assays is directly comparable with those in the MLA. At least for pharmaceuticals, it appears that the MLA does not generate as many positive results as commonly believed. This should be taken into consideration when comparing the performance of other in vitro genotoxicity tests, and perhaps more importantly, it is against this incidence that the performance and validation of novel in vitro genotoxicity tests should be judged.
The reasons for the discrepancy seen between the incidence of positive results in the MLA at AZ and that in the literature are not clear but there appear to be several possibilities. First, the quality of particularly some of the older studies included in retrospective reviews can be questioned. A recent review of the studies performed for the U.S. National Toxicology Programme (24) , which includes a significant number of the results cited by Kirkland et al., has shown that 211 of 342 results (61%) were uninterpretable due to inappropriate concentration selection or control responses. Hence in this reanalysis, only 74 of the original 163 positive calls were considered to be appropriate. This is not a censure of the review by Kirkland et al., but it does highlight the difficulty with making conclusions from retrospective analyses. Second, and possibly contributing to the poor quality of some of the published data, is the provenance of the mouse lymphoma cells used in different laboratories. Recent work has shown that the sensitivity of L5178Y cells to test agents as indicated by in vitro micronucleus induction can depend on the source. For example, the non-carcinogen anthranilic acid was found to be genotoxic when tested using L5178Y cells from an established commercial repository, but negative when tested using cells supplied by AZ (Dr P. Fowler, personal communication; Covance Laboratories Limited). The cells from AZ can be shown to have been grown for no more than 4 weeks in continuous culture from a sample provided by Clive over 30 years ago, but the provenance of cells used in many laboratories may not be so well known. Finally, it is possible that the incidence of positives with compounds in the chemical space occupied by potential drug substances differs from that with the compounds in the literature that have been tested for other reasons.
It would obviously be advantageous to be able to predict MLA activity using in silico screening. Further, it appears that some regulatory authorities may have requested the MLA on impurities in drug substances on the basis of alerts in unspecified structural alert relationship systems. Consequently, results for the compounds tested in this laboratory were analysed using MC4PC and it was disappointing that its predictivity was such that, in its current state of development, it cannot be considered sufficiently accurate to be used to predict the MLA activity of pharmaceuticals, their metabolites or potential impurities. The sensitivity was similar to that previously reported $60-70%, but the specificity (38%) and overall concordance (42%) were much lower than the reported $70% for both specificity and concordance (25, 26) . In fact, MC4PC predicted 62% of all compounds, whether actually positive or negative, to be positive.
In conclusion, of 355 compounds tested in the MLA in this laboratory, only 52 (15%) gave positive results; even if it is assumed that all of these are non-carcinogens, the incidence of The incidence of positive results in the MLA false positive predictions of carcinogenicity must be much lower than the 61% apparent from analysis of the literature. Further, only 19 compounds (5% of total) were positive by a mechanism that could not be related to the compound's primary pharmacological activity or positive responses in other genotoxicity assays. Although not certain, it is likely that the positive results obtained with compounds known to inhibit topisomerases, kinases or DNA repair are due to their pharmacology. Currently, there are few practical screens for these activities and, if better tests were to be developed, it is possible that the occurrence of inexplicable positive results in the MLA could be reduced further.
